EscharEx Investor Breakfast
Tuesday, July 12, 2022
8:00 AM - 9:30 AM EDT
Location: St. Regis Hotel Two E 55th St.
New York, NY 10022
Hosted by Mediwound (NASDAQ: MDWD)
|
Join us for the MediWound EscharEx Investor Day, featuring presentations by Key Opinion Leaders (KOLs) John C. Lantis, M.D. (Mount Sinai West Hospital and Icahn School of Medicine), Cyaandi R. Dove, D.P.M. (Advanced Wound & Ankle Center, Las Vegas), Robert J. Snyder, D.P.M., M.Sc. (Barry University) and Kevin Feng (Oliver Wyman).
These external experts will discuss the current wound debridement practice, the unmet need, the EscharEx recent clinical study results, as well as case studies that highlight the treatment experience.
In addition, KOLs will discuss the potential positioning of EscharEx for the treatment of patients and its competitive advantages while emphasizing its significant market opportunity.
EscharEx is a next-generation bioactive topical therapeutic under development in the U.S. for debridement of chronic and hard to heal wounds.
MediWound's Chief Executive Officer, Ofer Gonen, will moderate the session and provide a company update and discuss future strategic plans.
An expert panel Q&A session will follow the formal presentations.
|
|
Interested parties unable to attend the in-person Investor Day will be able to view and listen to the webcast by clicking here.
|
|
Further information to be provided upon registration
|
|
John C. Lantis II, M.D.
John C. Lantis II, M.D., is currently the site Chief of Surgery at Mount Sinai West Hospital, in mid-town Manhattan where he practices as a senior vascular surgeon. Prior to this he served as Vice Chairman for operations, for the Department of Surgery at both Mount Sinai West and Mount Sinai Morningside since 2014, and the chief of Vascular and Endovascular surgery since 2007. He attained the academic rank of Professor of Surgery first at Columbia University in 2013, and subsequently in 2014 at the Icahn School of Medicine. In addition as co-chair of the Cardiovascular and interventional radiology value analysis committee, he has served on the corporate steering committee for value analysis since 2014.
He is a world leader in limb salvage and lower extremity wound healing, which includes a very large breath of knowledge in regards to cellular and tissue based therapies and local and regional flap therapy. He has been a principal investigator on over 70 clinical trials; including having participated in most of the lower extremity stem cell therapy trials. He is frequently asked to speak internationally in regards to these subjects.
He is the Clinical Editor of WOUNDS and sits on the editorial boards of most of the major Wound journals. He is the past president of the New York Vascular Surgery Society, a founding member of the American Board of Wound Medicine and Surgery, and the Vascular Study Group of New York.
He is locally recognized for excellent outcomes in carotid surgery, and endovascular limb salvage. His practice also includes abdominal aortic aneurysm repair, vascular access for hemodialysis, complex head and neck reconstruction, major abdominal sarcoma resection, and advanced outpatient venous therapy.
Dr. Lantis leads the diabetic foot team, the amputation team and is his institution's principal consultant for the advanced wound care.
|
|
Cyaandi R. Dove, D.P.M.
Cyaandi R. Dove, D.P.M. currently runs a private practice in Las Vegas, Nevada. Her practice has a special focus in wound healing and limb preservation. Her medical practice also engages in industry sponsored clinical trials. Dr. Dove has served as a Principal Investigator in nearly 50 clinical trials, over the past twenty years.
She earned the Degree of Doctor of Podiatric Medicine at California College of Podiatric Medicine in San Francisco, CA, She also completed her Post Graduate Training at The University of Texas, Health Science Center in San Antonio, Texas under the tutelage of Dr. Lawrence Harkless. She completed a surgical fellowship at North General Hospital, in New York, NY.
Before opening her practice, Dr. Dove was the director of podiatry at the Diabetic foot and Ankle Center - Hospital for Joint Disease - NYU. Concurrently, she served as the sub-investigator for multiple Phase I-IV clinical trials. Dr. Dove has multiple publications in the Lancet and other peer-reviewed journals.
|
|
Robert J. Snyder, D.P.M., M.Sc.
Robert J. Snyder, D.P.M., M.Sc. is Professor and Director of Clinical Research and Fellowship Director in Wound Care and Research at Barry University School of Podiatric Medicine. He is certified in foot and ankle surgery by the American Board of Podiatric Surgery and is also a board certified wound specialist. Dr Snyder is past-president of the Association for the Advancement of Wound Care and past-president of the American Board of Wound Management, the certifying body for Wound Care Specialists. In addition to his doctorate, he holds an MSc in Wound Healing and Tissue Science from Cardiff University School of Medicine. His expertise at Cardiff, Wales, was further acknowledged by appointment as Honorary Senior Lecturer. To constantly expand his knowledge and stay current in all aspects of healthcare, he has completed an MBA in Health Management. Dr. Snyder is a key opinion leader and sought after speaker, lecturing extensively throughout the United States and abroad. He has been recognized with many awards for his contribution to the profession. Dr. Snyder has published several book chapters and over 165 papers in peer reviewed and trade journals on wound care. He serves as Associate Editor for JAPMA and is on the editorial advisory boards of Wound Management & Prevention, Wounds and Podiatry Management. He is also a periodic reviewer for the Lancet and NEJM. He has been a Principal Investigator on more than 50 randomized controlled trials for innovative wound healing modalities and therapies. In 2018, Dr. Snyder was inducted as a Faculty Fellow of the Royal College of Physicians & Surgeons (Glasgow).
|
|
Kevin Feng
Kevin Feng is an Associate in Oliver Wyman’s Health & Life Sciences practice, serving pharmaceutical and biotechnology clients on a range of R&D and commercial strategy projects. He has extensive experience deriving insights from market research to inform clinical development strategies, launch planning, and forecasting efforts. Kevin has been deeply involved in supporting the MediWound team to evaluate the U.S. wound care & debridement market landscape and to assess the opportunity for EscharEx.
|
|
|
|
250 West 55th Street, Suite 3401
New York, NY 10019
|
|
Copyright © 2022 LifeSci Advisors, LLC, All rights reserved.
This message contains confidential and proprietary information and is intended only for the individual named. If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.
|
|
|
|
|
|
|